We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A Randomized, Double-Blind, Placebo-Controlled Crossover Study of Coenzyme Q<sub>10</sub> Therapy in Hypertensive Patients With the Metabolic Syndrome.
- Authors
Young, Joanna M.; Florkowski, Christopher M.; Molyneux, Sarah L.; McEwan, Roberta G.; Frampton, Christopher M.; Nicholls, M. Gary; Scott, Russell S.; George, Peter M.
- Abstract
BackgroundOur aim was to examine the effects of adjunctive coenzyme Q10 therapy on 24-h ambulatory blood pressure (BP) in subjects with the metabolic syndrome and inadequate BP control.MethodsIn a randomized, double-blind, placebo-controlled 12-week crossover trial, coenzyme Q10 (100 mg twice daily) or placebo was administrated to 30 subjects with the metabolic syndrome, and inadequate BP control (an average clinic BP of ≥140 systolic mm Hg or ≥130 mm Hg for patients with type 2 diabetes) while taking an unchanged, conventional antihypertensive regimen. Clinic and 24-h ambulatory BP were assessed pre- and post-treatment phases. The primary outcomes were the changes in 24-h systolic and diastolic BP during adjunctive therapy with coenzyme Q10 vs. placebo and prespecified secondary outcomes included changes in BP loads.ResultsCompared with placebo, treatment with coenzyme Q10 was not associated with statistically significant reductions in systolic (P = 0.60) or diastolic 24-h ambulatory BP (P = 0.12) or heart rate (P = 0.10), although daytime diastolic BP loads, were significantly lower during coenzyme Q10 administration with thresholds set at >90 mm Hg (P = 0.007) and ≥85 mm Hg (P = 0.03). Coenzyme Q10 was well tolerated and was not associated with any clinically relevant changes in safety parameters.ConclusionsAlthough it is possible that coenzyme Q10 may improve BP control under some circumstances, any effects are likely to be smaller than reported in previous meta-analyses. Furthermore, our data suggest that coenzyme Q10 is not currently indicated as adjunctive antihypertensive treatment for patients with the metabolic syndrome whose BP control is inadequate, despite regular antihypertensive therapy.American Journal of Hypertension (2012). doi:10.1038/ajh.2011.209
- Publication
American Journal of Hypertension, 2012, Vol 25, Issue 2, p261
- ISSN
0895-7061
- Publication type
Academic Journal
- DOI
10.1038/ajh.2011.209